Prepared to Take More and More Gain Investor Can Observe ( SRPT, VRNG, BIOL, OCN )

Los Angelas, CA -- (SBWIRE) -- 10/04/2012 -- Sarepta Therapeut (NGM:SRPT) is very active today and traded between $29.26 - 45.00 with total traded volume of 27916940 shares. At a current price of 44.93, SRPT is +29.94 - +199.73% from the previous close of $14.99. Moreover, At Current Market Price, SRPT is in distance of +213.60% from its 50-day Moving Average price of $14.3271 and +476.46% from its 200-day Moving Average price of $7.7942. Sarepta Therapeutics, Inc. (SRPT), one of our swing trades, was the star of the day on Wednesday, jumping 200% on positive news of a new drug that may be a cure for muscular dystrophy. It was up 29.94 to 44.93, on 27.9 million shares. Just a couple days ago when it broke out of a flag, it pulled back for a day or so, and then exploded on Wednesday. When we see these kinds of patterns with a big breakaway, we often see a stair-step up. It may pull back, to the 38-40 range, consolidate and move higher to the mid 50’s, and then high 60’s, eventually.

Can Investor Take A Risk To Buy or Hold This Stock : Find Out Here

Vringo, Inc. Comm (AMEX:VRNG) is very active today and traded between $3.01 - 4.30 with total traded volume of 25568372 shares. At a current price of 4.30, VRNG is +1.21 - +39.16% from the previous close of $3.09. Moreover, At Current Market Price, VRNG is in distance of +28.63% from its 50-day Moving Average price of $3.3429 and +27.81% from its 200-day Moving Average price of $3.3645. Shares of Vringo (NASDAQ: VRNG), the New York-based developer of video ringtones and holder of mobile and Internet search patents, rose 39.16% Wednesday on 7 times average volume. Vringo received a favorable court ruling on Wednesday, as the judge overseeing the company's patent dispute with Google denied Google's request for a summary judgment. The parties were ordered to engage in settlement discussions between United States magistrate, Judge Lawrence R. Leonard at 10:30am, Tuesday October 9, 2012.

Can Investor Take A Risk To Buy or Hold This Stock : Find Out Here

Biolase, Inc. (NCM:BIOL) is +0.56 - +33.73% from the previous close of $1.66. It traded between $1.83 - 2.371 with total traded volume of 3646818 shares. Keep a close eye on BIOL, as the stock has been showing unusual moves over the past weeks. At Current market price, BIOL has recovered +48.74% from its 52-week Low of 1.4925 and has Pulled back -42.22% from its 52-week high of 3.8421. Biolase (NASDAQ: BIOL), the Irvine, CA dental laser company, rose 33.73% Wednesday on 49 times average volume. Biolase, the world's leading dental laser manufacturer and distributor, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration and Conformité Européene Mark approval for its EPIC 10™ diode soft tissue laser. BIOLASE initiated commercial sales in the final days of the third quarter of 2012 throughout the European Union and in those Asian and Latin American countries that recognize the CE Mark. The Company received notification of clearance from the FDA on October 1, 2012, and immediately began offering the EPIC 10 for sale in the U.S

Can Investor Take A Risk To Buy or Hold This Stock : Find Out Here

Ocwen Financial C (NYSE:OCN) reported EPS of 0.747. For the Current Fiscal year, the company is expected to report EPS of 1.47. For the Next Quarter and Next Year, the company is expected to report EPS of 0.52 and 2.82 respectively. At Current Market Price, OCN is in distance of +31.10% from its 50-day Moving Average price of $26.606 and +77.95% from its 200-day Moving Average price of $19.6008. Ocwen Financial Corp. Ocwen Financial Corporation(NYSE:OCN) stock climbed 14.64% to $33.20. The shares of OCN touched a new 52 week high at $34.98 in the early hour. OCN and private equity firm WL Ross & Co. LLC today announced that they have entered into an agreement whereby Ocwen will acquire Homeward Residential Holdings, Inc., including its various residential mortgage loan servicing and origination operating subsidiaries, for approximately $588 million in cash and $162 million in Ocwen convertible preferred stock. Additionally, Zacks restated their neutral rating on shares of Ocwen Financial in a report issued last week. They currently have a $29.00 target price on the stock.

Can Investor Take A Risk To Buy or Hold This Stock : Find Out Here

Disclaimer:
Neither HotPennyStockNews.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by HotPennyStockNews.com, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation. HotPennyStockNews.com makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through HotPennyStockNews.com. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein..

Contact:
hotpennystocknews.com
info@hotpennystocknews.com